CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will
present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 2:50 pm MT in
Scottsdale, Arizona.
The Credit Suisse Healthcare Conference will be webcast live under the investor relations section of Solid Biosciences’ website
at www.solidbio.com and will be archived there following the presentation for 30 days.
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy
(DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science,
technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs
across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices.
For more information, please visit www.solidbio.com.
Media Contact:
Solid Biosciences
Kate Niazi-Sai
617-337-4680
media@solidbio.com
Investor Contact:
Kendall Investor Relations
Carlo Tanzi, Ph.D.
617-337-4680
investors@solidbio.com
